Erasca

ERAS

Market cap $2.73B

ERAS stock jumps 42% in a week after early phase I solid tumors study data for ERAS-0015 shows encouraging responses, favourable safety and faster-than-expected enrollment.

Erasca's general counsel and corporate secretary sold 120,000 shares of the biotech for $670,800 in gross proceeds on Jan. 7. The sale resulted from an option exercise with shares immediately sold; no indirect holdings or gifts were involved.

Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for ERAS-0015 during dose escalation

Erasca Inc. (NASDAQ: ERAS) shares on Wednesday jumped close to 60% to $6.12. On Thursday, the stock fell as low as $4.33.

SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 44th Annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis in San Francisco, California.

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 8th Annual Evercore Healthcare Conference being held at the Loews Coral Gables Hotel in Coral Gables, FL. Management will participate in a fireside chat on Wednesday, December 3, 2025, at 10:25 am Eastern Time and will also participate in one-on-one investor meetings.

U.S. composition of matter patent protection through 2043 for potential best-in-class pan-RAS molecular glue ERAS-0015 Strengthened scientific leadership with promotion of Robert Shoemaker, Ph.D., to chief scientific officer Initial Phase 1 monotherapy data for ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 Robust balance sheet with cash, cash equivalents, and marketable securities of $362 million as of September 30, 2025 is expected to fund operations into H2 2028 SAN DIEGO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter ended September 30, 2025.

The issued patent provides intellectual property protection for ERAS-0015 and related compositions until at least 2043  Initial Phase 1 monotherapy data for ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Patent and Trademark Office has issued Patent No. 12,458,647, titled “Macrocyclic Derivative And Use Thereof.

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in November 2025 and will also participate in one-on-one investor meetings at each of these conferences. Guggenheim 2nd Annual Healthcare Innovation Conference (November 10-12, 2025) Location: Boston, MA Format: Fireside Chat Date and Time: Tuesday, November 11, 2:00 pm Eastern Time Stifel 2025 Healthcare Conference (November 11-13, 2025) Location: New York, NYFormat: Fireside Chat Date and Time: Wednesday, November 12, 1:20 pm Eastern Time Jefferies Global Healthcare Conference (November 17-20, 2025) Location: London, UKFormat: Fireside ChatDate and Time: Wednesday, November 19, 10:30 am Greenwich Mean Time A live audio webcast of the events will be available online at Erasca.com/events.

SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference being held at the Sheraton New York Times Square in New York, NY.